Zywie LLC is a therapeutics company focused on the treatment of metabolic and neurodegenerative disorders known as Lysosomal Storage Diseases (LSDs), a multi-billion dollar market. Many of these disorders are characterized by protein misfolding, instability and impaired trafficking of proteins within cells. One approach to treatment is the application of pharmacological chaperones (PCs), small molecules that enter cells and serve as a molecular scaffolding in order to cause misfolded mutant proteins to fold and route correctly within the cell. Ambroxol stimulates TFEB which in turn stimulates the autophagy system to clear misfolded proteins.
Intellectual Property (IP)
Zywie has filed patents on deuterated forms of Ambroxol and halogenated forms of Ambroxol.